While immunotherapies have offered improved treatment outcomes for some cancer types, these agents have not provided a satisfying response for the majority of colorectal cancer patients. To better leverage the benefits of immunotherapy in our patients, we’re developing personalized approaches through vaccines and cellular therapies. Both of these treatment strategies are tailored to the genetic makeup of individual patient tumors. We’re also optimizing checkpoint inhibitor strategies through our neoadjuvant platform, in which patients are given checkpoint inhibitor drugs prior to surgical resection of their tumors. This platform will determine whether this approach offers treatment benefits to patients and will guide future strategies by providing our researchers with specific information regarding how tumors respond to immunotherapies.